Forth, a UK company focused on personalised biomarker tracking, has attracted £1.6m (US$2.2m) in a second round of funding from a consortium of UK and overseas investors including Australia-listed, Melbourne-based Trajan Group, a global developer and manufacturer of analytical and life sciences products and devices. Trajan has entered into a binding agreement to secure equity…
Home Healthcare Markets International News Australia: Trajan invests in UK-based Forth’s second funding round and gains seat...